Zhang Financial LLC Acquires Shares of 2,720 Jazz Pharmaceuticals PLC $JAZZ

Zhang Financial LLC acquired a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,720 shares of the specialty pharmaceutical company’s stock, valued at approximately $514,000.

Other hedge funds have also recently made changes to their positions in the company. Hilltop National Bank purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth about $36,000. LRI Investments LLC purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $38,000. Leonteq Securities AG bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $50,000. Root Financial Partners LLC boosted its holdings in shares of Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 89 shares during the period. Finally, GoalVest Advisory LLC purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $51,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $247.53 on Friday. The business has a fifty day moving average of $235.11 and a 200 day moving average of $200.42. The stock has a market cap of $15.55 billion, a P/E ratio of -12,370.31, a PEG ratio of 0.22 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $250.49.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion for the quarter. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Analysts Set New Price Targets

JAZZ has been the topic of several recent research reports. Wells Fargo & Company increased their price target on Jazz Pharmaceuticals from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Canaccord Genuity Group assumed coverage on shares of Jazz Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $290.00 target price on the stock. Finally, TD Cowen raised their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $256.44.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director directly owned 18,449 shares of the company’s stock, valued at $4,446,209. The trade was a 9.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the transaction, the director owned 366,682 shares in the company, valued at $88,176,020.54. This represents a 1.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,098 shares of company stock worth $3,131,906 over the last ninety days. 4.10% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.